Managed Care Calendar
- AAPM 2010 Clinical Meeting
- AMCP 2010 Educational Conference
Poll
APA Conference
Long-Term Treatment with Asenapine Safe and Effective for Schizophrenia and Schizoaffective Disorder
New Orleans—An extension study that looked at the safety and efficacy of asenapine to treat patients with schizophrenia or schizoaffective disorder found that asenapine remains well tolerated and effective for up to 3 years of treatment. The study, presented in a poster at the recent APA meeting by Joep Schoemaker, MSc, of Merck Sharp & Dohme, confirmed previously published results that showed the safety and efficacy of asenapine for schizophrenia or schizoaffective disorder after 1 year of treatment.
The 1-year, double-blind,
REQUIP XL is an oral dopamine agonist medication for Parkinson’s disease and had demonstrated significant improvement in the symptoms of Parkinson’s disease.
The Role of Immune Function in the Changing Landscape of RRMS Therapies
Gastroesophageal reflux disease (GERD) is an important
managed care health concern because it is one of the most common gastrointestinal (GI) disorders in the United
States. GERD affects nearly 18.6 million Americans, according to a national healthcare database analysis.
Parkinson’s disease (PD) is a progressive
and disabling neurologic disorder. The disease is the most prevalent type of parkinsonism, a clinical syndrome caused by lesions in the basal ganglia, predominantly in the substantia nigra, which produces deficits in motor behavior.
